Results 41 to 50 of about 27,184 (256)

Tenofovir alafenamide clinical pharmacology

open access: yesInfezioni in Medicina, 2021
Tenofovir today exists in two pharmaceutical forms, such as Tenofovir disoproxil fumarate (TDF) and the newer Tenofovir alafenamide (TAF). The two different salts are required in order to promote intestinal absorption of the active molecule (TFV).
openaire   +2 more sources

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide

open access: yesDrugs in Context, 2021
Although tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) have been evaluated in various clinical trials, limited safety and efficacy data exist in real-world settings.
Sarah M Michienzi   +6 more
doaj   +1 more source

Bictegravir, Emtricitabine & Tenofovir Alafenamide-associated Acute Pancreatitis

open access: yesTranslation, 2023
Please view the PDF to see the formatted meeting abstract.
Abdulmajeed Alharbi
doaj   +1 more source

Jefferson Digital Commons quarterly report: January-March 2020 [PDF]

open access: yes, 2020
This quarterly report includes: New Look for the Jefferson Digital Commons Articles COVID-19 Working Papers Educational Materials From the Archives Grand Rounds and Lectures JeffMD Scholarly Inquiry Abstracts Journals and Newsletters Master of Public ...
Copeland, LIBT, James   +2 more
core   +1 more source

Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbidities [PDF]

open access: yes, 2016
Renal toxicity in a 73 year old man using tenofovir/emtricitabine (TDF/FTC) as pre-exposure prophylaxis (PrEP) is described. Reduced renal reserve, a higher exposure to co-medications and co-morbidities can present a challenge when assessing the risks ...
Barber, TJ   +5 more
core   +1 more source

Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration [PDF]

open access: yes, 2023
BACKGROUND: Tenofovir alafenamide is gradually replacing tenofovir disoproxil fumarate, both prodrugs of tenofovir, in HIV prevention and treatment. There is thus an interest in describing tenofovir pharmacokinetics (PK) and its variability in people ...
Alves Saldanha, Susana   +10 more
core   +1 more source

Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV

open access: yesJournal of Renal and Hepatic Disorders, 2018
Tenofovir disoproxil fumarate (TDF) is a common antiretroviral utilised in the treatment of human immunodeficiency virus (HIV) and hepatitis B infections.
Nicole Marie Lioufas   +3 more
doaj   +1 more source

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide

open access: yesJournal of the International Association of Providers of AIDS Care, 2020
HIV is a serious chronic medical condition. Significant improvements in antiretroviral therapy have led to a transformation in its management. No curative treatment is available for HIV, and lifelong therapy is required with a combination of agents to ...
Chanie Wassner PharmD, BCCCP, BCIDP   +2 more
doaj   +1 more source

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott   +7 more
wiley   +1 more source

Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Serum HBV RNA levels at viral suppression predict HCC development in nucleos(t)ide analogue‐treated patients with chronic hepatitis B, outperforming Hepatitis B core‐related antigen alone. ABSTRACT Background Despite achieving undetectable hepatitis B virus (HBV) DNA levels with nucleos(t)ide analogue (NA) therapy, patients with chronic hepatitis B ...
Takashi Kumada   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy